ABEMACICLIB

Pre-LaunchSM

abemaciclib

ANDATABLET
Lifecycle
Pre-Launch
Clinical Trials
20

Mechanism of Action

cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In…

Indications (1)

Clinical Trials (5)

NCT07100106Phase 1/2Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Started Oct 2025
285 enrolled
Breast Cancer
NCT05940493Phase 2Recruiting

Abemaciclib in Newly Diagnosed Meningioma Patients

Started Mar 2025
72 enrolled
Meningioma
NCT06810544Phase 1/2Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Started Mar 2025
191 enrolled
Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4 more
NCT06025747Phase 1Recruiting

Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma

Started Mar 2025
18 enrolled
Retroperitoneal Sarcoma
NCT06835972Phase 1/2Recruiting

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Started Feb 2025
43 enrolled
Metastatic Renal Cell CarcinomaTranslocation Renal Cell Carcinoma